Leidos (NYSE: LDOS) has been awarded a potential five-year, $23.7 million contract to support the U.S. Agency for International Development‘s efforts to research and develop a vaccine against malaria.
The company said Monday it will provide scientific and management services for USAID’s Malaria Vaccine Development Program under the cost-plus-fixed-fee contract.
Jerry Hogge, Leidos health deputy group president, said the company brings decades of life sciences technology and experience to the USAID program.
Leidos said the work to occur in Frederick, Maryland, could also evaluate malaria vaccine candidates during preclinical studies and clinical and field trials.
The company’s life sciences team supports medical product R&D efforts at the National Institutes of Health and the departments of Defense and Homeland Security.